This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Obesity
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
-
Valley Clinical Trials, Covina, California, United States, 91723
Diablo Clinical Research, Inc., Walnut Creek, California, United States, 94598
Yale University School Of Medicine, New Haven, Connecticut, United States, 06519
East West Medical Research Institute_Honolulu, Honolulu, Hawaii, United States, 96814
L-MARC Research Center, Louisville, Kentucky, United States, 40213
StudyMetrix Research LLC, Saint Peters, Missouri, United States, 63303
Spartanburg Medical Research, Spartanburg, South Carolina, United States, 29303
Holston Medical Group_Bristol, Bristol, Tennessee, United States, 37620
North Texas Endocrine Center, Dallas, Texas, United States, 75231
Washington Cntr Weight Mgmt, Arlington, Virginia, United States, 22206
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Novo Nordisk A/S,
Clinical Transparency (dept. 2834), STUDY_DIRECTOR, Novo Nordisk A/S
2028-11-17